Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
877 PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth
Compose a Response to This Article
Other responses
No responses have been published for this article.